Monica Xu

• Represented Aureka Biotechnologies on its US$23+ million Series A financing led by 5Y Capital (formerly Morningside Capital)
• Represented Full-Life Technologies Limited on its US$8 million Series Seed financing led by Chengwei Capital, its US$37 million Series A financing led by HongShan, its US$47.3 million series B financing co-led by AZ-CICC and Prosperity7 and its US$50 million series C financing led by Junson Capital as well as frequent daily general corporate matters
• Represented Alphagen Therapeutics on its US$35 million Series A financing led by Genesis Capital and Tencent
• Represented Manus.ai on its US$74+ million Series B financing led by Benchmark
• Represented Angitia Biopharmaceuticals on its $120 million Series C financing led by Bain Capital
• Represented ProfoundBio on its US$10+ million Series Pre-A financing led by K2VC, US$55+ million Series A financing led by LAV, US$70 million Series A+ financing led by HongShan, US$112 million Series B financing led by Ally Bridge Group and $1.8 billion acquisition by Genmab
• Represented Chimagen Biosciences in its Series B financing led by Foresite Capital and Lilly Asia Ventures
• Represented Eccogene on its US$25 million Series C financing led by AstraZeneca
• Represented InxMed Limited on its US$49.48 million Series B financing led by SDIC, US$36 million Series C financing led by Fosun and its IPO and listing on Hong Kong Stock Exchange
• Represented TandemAI Limited on its US$10 million Series Seed financing led by Chengwei Capital, US$15 million Series Pre-A financing led by Orbimed Asia, US$35 million Series A financing led by Qiming Ventures as well as frequent daily general corporate matters
• Represented Ambrx Biopharma, Inc. (NYSE: AMAM, then acquired by Johnson & Johnson) on its US$100 million pre-IPO cross-over Series B financing led by WuXi PharmaTech and Fidelity, its cross-border reorganization in connection with its US$126 million listing on Nasdaq as well as frequent daily general corporate matters
• Represented Gracell Biotechnologies Inc. (NASDAQ: GRCL, then acquired by AstraZeneca) on its US$120 million pre-IPO Series C financing led by Wellington, OrbiMed and Morningside
• Represented Akeso, Inc. (HKEX: 9926.HK) on its RMB65 million (US$10m) Series A financing, RMB30 million (US$4.6m) Series B financing, US$150 million Series D financing, RMB690 million (US$106m) joint venture with Chia Tai Tianqing, collaboration agreement with Pfizer, as well as frequent daily general corporate matters
• Represented EpimAb Biotherapeutics Inc. on its US$1.5 million Series Seed financing, US$1 million Series Seed Plus financing, US$25 million Series A financing led by Oriza Capital and Decheng Capital, US$74 million Series B financing co-led by SDIC Fund and Sherpa Healthcare Partners, US$120 million Series C financing co-led by China Merchants Bank International and Mirae Asset Financial Group, US$23 million convertible note financing as well as frequent daily general corporate matters
• Represented GraniteAsia (formerly GGV Capital) on approximately 150 investment transactions and various post-investment/exit matters across the globe in many industrial sectors, including without limitation US$127 million Series D financing of Keep Inc., US$100 million Series C financing of Musical.ly and its US$1b acquisition by ByteDance (then rebranded to TikTok), US$130 million Series E financing and $270 million Series F+ financing of Kanzhun Ltd. (NASDAQ: BZ, an operator of Boss Zhipin), US$20 million Series F financing of Xiaohongshu and several secondary sales of shares in Xiaohongshu, US$45.5 million secondary sale of Series A-15 preferred shares of Xiaoju Kuaizhi, Inc. (DiDi Taxi), US$10.4 million Series A financing and $25.5 million Series B financing of Niu (NASDAQ: NIU), US$750 million Series E financing of Zuoyebang, US$550 million Series C financing of Orca Security, US$264.33 million Series A financing of HT Flying Car Inc., US$200 million Series C financing of Geek+, US$150 million Series C financing of RUANGGURU, US$25 million secondary purchase of Series A-1 preferred shares of Full Truck Alliance Co. Ltd. (NYSE: YMM), US$22.95 million Series C+ financing of Kascend Holding Inc. (Chushou), US$10 million Series A financing of Ehang Holdings Limited (NASDAQ: EH), US$10 million Series A financing of Thunes Ltd., US$57 million Series C financing of Soulgate, Inc. (NASDAQ: SSR, an operator of Soul), US$85 million equity financing of Huohua Siwei, US$100 million Series C financing of Tujia, and many others
• Represented Qiming Venture Partners on various investment transactions in technology and life science companies, including without limitation imToken, Blueware, Belief Biomed, Tupos, Oricell, DeBank, Sesame, Infinity Stones, and many others
• Represented Eight Roads Ventures on various investment transactions in technology and life science companies, including US$200.32 million Series B financing of Sironax Ltd., US$3 million Series Pre-B financing of KnowYourself Inc., US$13.8 million Series B financing of Kyligence, Inc., US$50 million Series A-3 financing of a biopharma company, US$38 million Series A-3 financing of Adcentrx, etc.
• Represented Boyu Capital on multiple equity investments in and newco transactions with life science companies
• Represented Lily Asia Ventures on various investment transactions in life science companies, including US$20 million Series Seed financing of Synnovation Therapeutics, Inc. and US$155 million series B investment of ArriVent Biopharma and many others
• Represented Pulnovo Medical Limited on its US$40 million Series B financing led by Yuanbio Venture
• Represented Lupeng Pharmaceutical Ltd. on its US$35 million Series Pre-B financing led by Temasek and Kaitai Capital
• Represented Ablaze Pharmaceuticals Inc., the China subsidiary of RayzeBio, on its US$75 million Series A financing
• Represented DeltaHealth China Limited, a hospital incubated by Eight Roads Ventures, on its US$45.8 million Series D financing, US$82.8 million Series E financing, US$120.78 million Series E-1 financing, US$30 million convertible note financing as well as frequent daily general corporate matters
• Represented Decheng Capital on various investment transactions in the Greater China area, including US$26.9 million Series A financing of Take2 Holdings Limited, US$30 million Series C equity financing of IMPACT Therapeutics, Inc., US$34 million Series Seed Plus financing of AccuGen Group, etc.
• Represented Andreesen Horowitz (a16z) on multiple equity investments in technology companies
• Represented Sanegene Bio on its US$38.5 million Series A financing led by Hillhouse
• Represented GrabTaxi Holdings Pte. Ltd. on its US$53.58 million Series C preferred share financing led by Tiger Global, Hillhouse, GGV Capital and Vertex Asia, US$250 million Series D preferred share financing led by SoftBank, US$20 million Series D-1 preferred share financing led by DiDi Taxi, US$250 million Series E preferred share financing led by SoftBank, Coatue, Hillhouse as well as frequent daily general corporate matters
• Represented Carousell Pte. Ltd. on its US$35.8 million Series B financing and US$44.5 million Series C financing led Rakuten Aisa, Sequoia Capital, Golden Gate Ventures, as well as various general corporate matters
• Represented LAIX Inc. (formerly named LingoChamp Inc., NYSE: LAIX) on its US$1.465 million Series Seed financing and US$10 million Series A financing led by GGV Capital and IDG and US$28.92 million Series B financing led by Trustbridge Partners
• Represented Paidy Inc. (formerly named Exchange Corporation Holdings Limited) on its US$2.23 million Series A financing led by Arbor Ventures, US$4.5 million Series A-10 financing led by SIG, US$7.6 million Series B financing led by Japan Ventures and US$55 million Series C financing led by ITOCHU Corporation
• Represented Welab Holdings Limited on its US$10.85 million Series A financing, US$4.75 million Series A-2 financing, US$97.5 million Series B financing, US$44.5 million Series B-1 financing and US$15 million convertible note financing
• Represented Cargene Biopharma Inc. on its US$18.6 million Series Pre-A financing led by BioTrack Capital and various general corporate matters
• Represented numerous other top-tier venture capital funds and other investors in their investments in various industry sectors around the globe, including Horizons Ventures, Orbimed Asia, Temasek Capital, Wuxi Healthcare Ventures, Biotrack Capital, Lightspeed, HongShan, Square Peg Capital, Arbor Partners Asia, Pappas Capital, Karst Peak Capital, Telstra Ventures, Matrix Partners, SIG, NVIDIA Corporation, Ceyuan Ventures, Chengwei Ventures/Gordian Ventures, Shunwei Capital, DiNova Venture, Black Opal Ventures and Abu Dhabi Developmental Holding Company, etc.

Mergers & Acquisitions

• Represented Inmagene Biopharmaceuticals on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA)
• Represented Chimagen Biosciences on its agreement to sell CMG1A46, a clinical-stage dual CD19 and CD20-targeted T-cell engager (TCE), to GSK with US$300 million upfront and US$550 million development and commercial milestone payments.
• Represented ProfoundBio on its $1.8 billion all-cash acquisition by Genmab (NASDAQ: GMAB)
• Represented TandemAI Limited on its acquisition of Perpetual Medicines, an AI drug discovery company
• Represented Full-Life Technologies Limited, on its acquisition of Focus-X
• Represented GraniteAsia (formerly named GGV Capital), as an exit shareholder, on the sale of Conic AI Technology
• Represented Eight Roads Ventures, as an exit shareholder, on the $520 million all cash sale of Invetx by Dechra
• Represented Gracell Biotechnologies on its $1.2 billion acquisition by AstraZeneca
• Represented Granite Asia (formerly named GGV Capital) on the short-form reverse merger and de-listing of LAIX Inc. (formerly named LingoChamp Inc., NYSE: LAIX)
• Represented Cytek BioSciences, Inc. (NASDAQ: CTKB) on its asset sale to Cytoville, Inc.
• Represented dMedScience, LLC on connection with its US$16m purchase of assets from Target Health Inc.
• Represented Lomotif Private Limited on connection with its US$75 million sale of 60% of outstanding share capital to Zash Global Media and Entertainment Corp.
• Represented ResMed Ltd on connection with its US$150 million acquisition of a respiratory products manufacturer

Joint Venture, Corporate Partnering and Other Strategic Transactions

• Represented Qiming Venture Partners on its formation of and investment into Vignette Bio (NewCo), a clinical-stage NewCo, with Foresite Capital, Samsara Biocapital, and Mirae Asset Capital Life Science, and in Vignette Bio’s licensing agreement with EpimAb Biotherapeutic for its BCMA-targeting T-cell engager (TCE) EMB-06
• Represented Boyu Capital in its various newco transactions
• Represented Akeso, Inc. (HKEX: 9926.HK) on its collaboration agreement with Pfizer Inc., its establishment of a RMB690 million (US$106m) joint venture with Chia Tai Tianqing Pharma (CTTQ) and various other life science partnering transactions
• Represented KeyMed Biosciences, Inc. (HKEX: 02162HK) on its joint venture with Lepu Biopharma Co., Ltd. and various other licensing and collaboration transactions with leading biopharma companies
• Represented Johnson Controls (NYSE: JCI) on the formation of a $7.5 billion joint venture with SAIC’s Yanfeng Automotive Trim Systems, the component group of Shanghai Automotive Industry Corporation
• Represented Quark Pharmaceuticals, Inc. on its establishment of a US$8 million joint venture (Kunshan RiboQuark Pharmaceutical Technology Co., Ltd.)
• Represented Crown Bioscience, Inc. on its various transactions, including therapeutic business spin-off
• Represented Shenzhen Shenxin Biotechnology Co., Ltd. (InnoRNA) on its collaboration transaction with Chongqing Zhifei Biological Products Co., Ltd. (SZSE: 300122) for COVID-19 mRNA vaccine development, manufacture and commercialization
• Represented Shenzhen Shenxin Biotechnology Co., Ltd. (InnoRNA) on its R&D and commercialization collaboration and license transaction with BeiGene, Ltd. (NASDAQ: BGNE/688235.HK) for development and commercialization of certain mRNA-LNPs
• Represented Shanghai Hile Bio-Technology Joint Stock Company on the formation of a RMB300 million (US$46m) joint venture (Yangling Jinhai Bio-Technology Co. Ltd.) with Biogénesis Bagó S.A., an Argentinian pharmaceutical company, to manufacture and distribute animal vaccines in China
• Represented F1 Oncology, Inc., an affiliate of Exuma Biotechnology, on its collaboration and sublicense transaction

Capital Markets

• Represented the underwriters of Duality Biologics (DualityBio), in connection with its HK$1.64 billion global initial public offering
• Represented Gracell Biotechnologies Inc. (then acquired by AstraZeneca) on its US$209 million listing on Nasdaq
• Represented Ambrx Biopharma (then acquired by Johnson & Johnson) on its $126 million initial public offering in Nasdaq